BioPharmX Says Phase 2b Trial Met Endpoints

Biopharmx Corp BPMX shares spiked higher Tuesday morning after the company announced its Phase 2b trial of BPX-04 for Populopustular Rosacea has met both primary and secondary endpoints and was well tolerated.

This news pushed BioPharmX from 88 cents to $1.27 per share, but the stock traded around 84 cents at time of publication.

Get Started

Start Futures Trading Fast — with a $200 Bonus

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live markets with lightning-fast execution, low commissions, and full regulatory protection.

Get Started

Related Links:

Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues

Acer Therapeutics Shares Plunge On FDA Complete Response Letter